This is a routine annual filing with no new material information. Traders should focus on the Q4 FY2026 earnings call transcript (filed May 18, 2026) for any operational updates. The 20-F itself provides no immediate trading catalyst.
RDY drugs
RDY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $13.26entry
- T+1 · 6mo ago −1.73%α −1.88% · $13.03
- T+5 · 5mo ago −0.15%α +2.60% · $13.24
- T+20 · 5mo ago +9.28%α +10.57% · $14.49
- T+60 · 3mo ago −6.94%α −8.17% · $12.34
Price Chart
How similar events traded
Executive Summary
Dr. Reddy's filed its annual Form 20-F for the fiscal year ended March 31, 2026, a routine annual report with no new material financial disclosures beyond what was previously reported in its Q4 FY2026 earnings. The filing confirms 834,656,970 equity shares outstanding and the company's status as a large accelerated filer. No material changes, restatements, or going-concern issues are noted.
Key Facts
- Annual report for fiscal year ended March 31, 2026, filed on Form 20-F
- 834,656,970 equity shares outstanding as of March 31, 2026
- Company confirms it is a large accelerated filer and has filed all required reports
- No restatements, error corrections, or going-concern issues disclosed
- Financial statements prepared under IFRS as issued by IASB
- Convenience translation rate: US$1 = Rs. 93.83 as of March 31, 2026
Financial Impact
No new financial figures disclosed in this filing beyond previously reported Q4 FY2026 results
Risk Factors
- Risk factors disclosed include pricing pressure, regulatory inspections, patent litigation, and geopolitical instability in Russia/Ukraine and Middle East
- U.S. FDA issued a complete response letter for biosimilar rituximab BLA in November 2024; additional response submitted February 2026 with no approval timeline certainty
- Potential impact from U.S. executive order on most-favored-nation drug pricing (May 12, 2025) remains uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001575872-26-000381 |
| Document: 0001575872-26-000381-index.html | 0001575872-26-000381 |
| Document: 0001575872-26-000381.txt | 0001575872-26-000381 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers